exchang
protein
directli
activ
camp
epac
guanin
nucleotid
exchang
factor
mediat
effect
pivot
second
messeng
camp
therebi
regul
wide
varieti
intracellular
physiolog
pathophysiolog
process
seri
novel
cyanid
epac
antagonist
synthes
evalu
effort
optim
properti
previous
identifi
highthroughput
ht
hit
structureact
relationship
sar
analysi
led
discoveri
sever
activ
epac
antagonist
eg
low
micromolar
inhibitori
activ
inhibitor
may
serv
valuabl
pharmacolog
probe
facilit
effort
elucid
biolog
function
epac
develop
potenti
novel
therapeut
human
diseas
sar
result
also
reveal
modif
phenyl
ring
well
isoxazol
moieti
may
allow
develop
potent
epac
antagonist
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
et
al
hz
dt
j
hz
j
hz
dt
j
hz
c
ye
et
al
pivot
second
messeng
camp
regul
wide
rang
physiolog
patholog
process
via
signal
pathway
involv
mani
diseas
state
includ
cancer
diabet
inflamm
heart
failur
neurolog
disord
physiolog
effect
camp
mainli
transduc
three
differ
downstream
effector
includ
protein
kinas
pka
cyclic
nucleotideactiv
ion
channel
recent
discov
exchang
protein
directli
activ
camp
epac
activ
elev
intracellular
concentr
camp
epac
protein
act
guanin
nucleotid
exchang
factor
gef
catalyz
exchang
gdp
gtp
raslik
small
gtpase
therebi
control
rapmedi
biolog
process
two
isoform
epac
protein
identifi
code
two
independ
gene
matur
develop
tissu
mammal
distinct
express
pattern
also
known
campgefi
human
nearli
ubiquit
express
wherea
express
also
known
campgefii
human
rel
restrict
least
three
splice
variant
human
found
exhibit
confin
express
pattern
broadli
express
larg
found
brain
pituitari
pancreat
islet
contrast
far
detect
adren
testi
wherea
express
restrict
liver
sinc
discoveri
epac
protein
evok
signific
interest
toward
elucid
role
physiolog
process
pathogenesi
well
molecular
mechan
epac
activ
accumul
evid
demonstr
epac
protein
play
critic
role
insulin
secret
cardiac
contract
osteoclast
differenti
vascular
permeabl
neurotransmitt
releas
tregmedi
immun
suppress
integrinmedi
cell
adhes
cell
migrat
prolifer
cell
exocytosi
apoptosi
well
gene
transcript
chromosom
integr
meanwhil
substanti
number
smallmolecul
epac
modul
includ
variou
camp
analogu
newli
discov
epacspecif
antagonist
discov
exploit
uncov
biolog
function
epac
variou
camp
deriv
report
use
power
pharmacolog
tool
epacrel
research
howev
camp
analogu
epac
ligand
limit
use
due
lack
select
among
isoform
epac
potenti
offtarget
effect
recent
substanti
effort
made
focu
nonnucleotid
small
molecul
epacselect
isoformspecif
antagonist
thio
thio
epac
antagonist
quinolinecarboxaldehyd
inhibitor
mesitylsulfonyl
specif
antagonist
identifi
new
pharmacolog
probe
high
capabl
specif
inhibit
epac
activ
team
develop
autom
robust
sensit
fluorescencebas
highthroughput
screen
ht
assay
base
detect
dosedepend
chang
fluoresc
intens
fluoresc
cyclic
nucleotid
analogu
purifi
fulllength
protein
analyz
competit
activ
select
compound
evalu
abil
inhibit
campmedi
gef
activ
use
purifi
recombin
fulllength
protein
maybridg
hitfind
compound
librari
structur
divers
small
molecul
screen
among
cyanid
identifi
character
novel
noncycl
nucleotid
epacspecif
antagonist
effect
toward
pka
figur
nmr
spectroscopi
experi
also
verifi
specif
interact
camp
bind
domain
cbd
human
aa
dosedepend
compet
bind
ic
valu
presenc
camp
also
dosedepend
display
campmedi
gef
inhibitori
activ
fulllength
appar
ic
valu
respect
specif
epac
inhibitor
use
tool
compound
reveal
role
camp
regul
plasmodium
falciparum
merozoit
invas
human
erythrocyt
restor
endotheli
barrier
thrombininduc
hyperperm
uncov
function
epac
osteoclast
format
campdepend
regul
schwann
cell
prolifer
differenti
addit
field
biolog
function
investig
also
demonstr
specif
block
intracellular
akt
phosphoryl
epacmedi
activ
insulin
secret
pancreat
cell
treatment
pancreat
ductal
adenocarcinoma
pda
cell
obviou
effect
cell
prolifer
viabil
give
rise
signific
decreas
cell
migrat
invas
furthermor
employ
orthotop
metastat
pda
mous
model
found
reduc
local
distant
spread
mia
cell
significantli
decreas
metastasi
liver
dose
mgkg
via
ip
inject
week
compound
also
enhanc
leptin
signal
organotyp
hypothalam
slice
cultur
system
administr
wildtyp
mice
dose
mgkg
oral
gavag
week
significantli
reduc
plasma
leptin
moreov
treatment
nontox
concentr
attenu
format
cytopath
effect
significantli
reduc
viral
yield
effect
protect
permiss
cell
middl
east
respiratori
syndrom
coronaviru
merscov
infect
inhibit
viral
rna
replic
protein
express
merscov
without
affect
express
local
epac
protein
also
shown
hit
complet
recapitul
knockout
phenotyp
vivo
via
pharmacolog
inhibit
significantli
block
earli
stage
rickettsi
attach
invas
nonphagocyt
host
cell
treatment
dose
mgkg
via
ip
inject
day
significantli
protect
wildtyp
mice
rickettsi
infect
result
much
milder
diseas
manifest
dramat
improv
surviv
taken
togeth
find
support
compound
select
pharmacolog
probe
unravel
vivo
function
epac
may
provid
potenti
novel
therapeut
prevent
treatment
variou
human
diseas
includ
pancreat
cancer
diabet
obes
middl
east
respiratori
syndrom
coronaviru
infect
fatal
rickettsios
compound
display
excel
bioavail
low
toxic
anim
good
membran
permeabl
signific
inhibitori
effect
pde
weak
inhibitori
activ
toward
herg
enzym
combin
observ
support
notion
nonnucleotid
small
molecul
may
superior
advantag
term
offtarget
effect
select
toxic
tradit
camp
analogu
despit
potenti
concern
associ
protein
denatur
properti
high
concentr
extens
biochem
pharmacolog
studi
defin
therapeut
window
valid
inde
act
epacspecif
antagonist
therefor
imper
optim
ration
drug
design
approach
develop
advanc
lead
enhanc
activ
specif
well
better
druglik
properti
herein
report
chemic
optim
effort
use
ht
hit
chemic
lead
well
detail
structureact
relationship
sar
studi
seri
substitut
cyanid
analogu
sever
new
molecul
tertbutyl
n
cyanid
tertbutyl
acetohydrazonoyl
cyanid
acetohydrazonoyl
cyanid
identifi
potent
epac
antagonist
low
micromolar
inhibitori
activ
given
wellcharacter
xray
crystal
structur
inact
activ
form
protein
examin
predict
bind
mode
via
molecular
dock
studi
camp
bind
domain
b
activ
protein
use
autodock
vina
algorithm
therebi
understand
effect
interact
mode
cyanidebas
chemotyp
result
suggest
bind
inhibitor
protein
may
primarili
occur
two
termin
hydrophob
interact
uniqu
linker
present
work
focu
new
molecular
design
optim
aforement
two
main
termin
hydrophob
pharmacophor
moieti
group
isoxazol
well
explor
linker
systemat
chemic
modif
depict
figur
outlin
scheme
key
intermedi
gener
condens
commerci
avail
pinacolon
oxal
acid
diethyl
ester
presenc
nah
follow
oxim
hydroxylamin
hydrochlorid
subsequ
cycliz
heat
onepot
procedur
yield
ethyl
ester
convert
correspond
ketonitril
treatment
meli
base
ch
cn
cyanid
sourc
modifi
kowalsko
protocol
requisit
aromat
amin
treat
sodium
nitrit
n
hydrochlor
acid
give
correspond
aryldiazonium
chlorid
direct
coupl
aryldiazonium
salt
crude
cyanomethyl
keton
presenc
naoac
catalyst
afford
new
substitut
cyanid
deriv
yield
two
step
scheme
depict
scheme
amid
urea
carbohydrazid
pyrazol
prepar
novel
substitut
cyanid
analogu
bear
differ
linker
isoxazol
chlorobenzen
condens
commerci
avail
b
acid
presenc
edci
dipea
yield
correspond
intermedi
b
convert
coupl
salt
upon
treatment
naoac
yield
two
step
respect
amid
urea
prepar
condens
acid
yield
respect
compound
revers
amid
prepar
first
remov
protect
group
ester
follow
condens
presenc
hbtu
dipea
result
yield
two
step
hydrazinolysi
ester
condens
provid
carbohydrazid
uniqu
linker
yield
two
step
mask
keton
group
pyrazol
prepar
cycliz
linker
hydrazin
hydrat
reflux
ethanol
yield
newli
synthes
compound
evalu
abil
compet
bind
recombin
protein
determin
ic
valu
previou
hit
camp
use
refer
compound
data
almost
ident
previous
report
ic
valu
inhibit
respect
shown
tabl
initi
focus
investig
effect
variou
substitut
phenyl
ring
previou
hit
evalu
import
substitut
remov
phenyl
ring
lead
compound
loss
bind
affin
ic
adjust
either
compound
result
decreas
inhibitori
activ
comparison
suggest
proper
substitut
benefici
activ
next
explor
electron
effect
substitut
phenyl
ring
detail
replac
congen
bromo
fluoro
compound
led
slight
loss
activ
compar
wherea
increas
activ
compar
nonsubstitut
analogu
ic
valu
respect
compound
electronwithdraw
group
trifluoromethyl
nitro
led
approxim
increas
potenc
compar
ic
valu
respect
compound
ethyl
carboxyl
cyano
group
retain
similar
inhibitori
activ
howev
compound
acetyl
group
display
dramat
loss
activ
introduct
electrondon
group
methoxi
isom
hydroxymethyl
afford
compound
also
result
signific
loss
activ
interestingli
compound
methyl
group
potent
nonsubstitut
analogu
ic
result
suggest
phenyl
ring
toler
chemic
modif
either
electronwithdraw
donat
group
explor
effect
disubstitut
phenyl
ring
keep
introduc
anoth
chloro
group
compound
analogu
bear
best
bind
affin
obtain
potent
parent
compound
ic
valu
respect
explor
fluorin
compound
given
notabl
success
drug
discoveri
increas
number
fluorinecontain
drug
market
due
uniqu
natur
fluorin
fluorin
substitut
commonli
use
contemporari
medicin
chemistri
drug
design
alter
physicochem
conform
properti
well
gener
select
reactiv
develop
candid
therebi
improv
metabol
stabil
solubl
bioavail
proteinligand
interact
moreov
analogu
monosubstitut
sar
studi
also
exhibit
compar
potenc
compound
therefor
seri
compound
fluoro
trifluoromethyl
chloro
group
style
design
synthes
compound
compound
approxim
potent
hit
identifi
optim
substitut
phenyl
ring
maintain
good
potenc
direct
effort
tune
isoxazol
scaffold
compound
chosen
refer
compound
keep
constant
substitut
phenyl
ring
embark
explor
steric
hindranc
effect
substitut
isoxazol
ring
via
replac
tbutyl
group
refer
compound
methyl
cpropyl
chexyl
phenyl
group
shown
tabl
compound
three
small
parallel
seri
mainli
display
good
inhibitori
effect
order
tbu
chex
cpr
ph
among
compound
potent
hit
ic
valu
figur
notabl
compound
phenyl
substitut
total
inact
indic
conform
constrict
biaryl
moieti
may
unsuit
fit
shallow
hydrophob
pocket
epac
protein
result
suggest
appropri
bulki
alkyl
substitut
offer
suffici
lipophil
favor
ligand
interact
protein
amid
urea
carbohydrazid
pyrazol
repres
subseri
novel
substitut
cyanid
analogu
bear
differ
linkag
isoxazol
chlorobenzen
modif
linker
length
type
interestingli
compound
addit
nh
fragment
insert
linker
complet
inact
bind
tabl
linkag
includ
amid
urea
carbohydrazid
pyrazol
also
led
entir
loss
potenc
toward
protein
result
indic
length
shape
type
linkag
import
ligand
interact
protein
biolog
result
discuss
compound
identifi
potent
binder
ic
valu
lower
therefor
select
compound
togeth
hit
evalu
abil
inhibit
exchang
activ
shown
tabl
previou
hit
slightli
less
potent
toward
inhibit
ic
valu
interestingli
almost
select
newli
synthes
analogu
exhibit
significantli
enhanc
bind
affin
compar
among
compound
share
best
inhibitori
activ
inhibitor
ic
valu
figur
compound
ic
valu
lower
may
serv
valuabl
pharmacolog
tool
probe
function
epac
diseas
potenti
drug
candid
preclin
develop
examin
whether
synthes
substitut
cyanid
analogu
better
solubl
defin
therapeut
window
previous
report
hplc
analysi
method
employ
measur
solubl
sever
select
analogu
tabl
onepoint
calibr
perform
standard
known
concentr
sampl
compound
determin
concentr
indic
compound
sampl
limit
aqueou
solubl
maximum
concentr
around
wherea
possess
excel
solubl
ethanol
mgml
addit
anoth
two
chloro
atom
onto
phenyl
ring
enhanc
bind
affin
also
improv
aqueou
solubl
instanc
aqueou
solubl
analogu
phenyl
ring
enhanc
satur
concentr
deriv
respect
meanwhil
fluorin
compound
also
exhibit
improv
potenc
aqueou
solubl
particular
compound
phenyl
ring
display
significantli
improv
solubl
water
ethanol
satur
concentr
mgml
indic
approxim
improv
comparison
respect
tabl
sinc
robust
ht
assay
particularli
sensit
identifi
compound
directli
compet
bind
predict
compound
may
bind
camp
bind
domain
cbd
molecular
dock
studi
perform
help
us
better
understand
structureact
relationship
new
compound
toward
use
autodock
method
dock
result
reveal
new
compound
fit
nice
function
camp
bind
pocket
activ
pdb
code
character
bind
pose
select
analogu
case
studi
theoret
investig
shown
figur
hydrophob
cyclohexylisoxazolyl
moieti
interact
hydrophob
residu
phe
wherea
fragment
form
hydrophob
interact
residu
moreov
bind
mode
stabil
occurr
hydrogen
bond
nh
hydrogen
atom
linker
oxygen
atom
residu
result
full
agreement
establish
sar
data
hydrophob
group
isoxazolyl
moieti
phenyl
scaffold
well
type
linker
crucial
target
molecular
dock
studi
also
compli
previou
result
hit
overlay
analysi
two
ligand
depict
figur
given
critic
role
linker
dock
find
may
also
help
us
understand
amid
urea
carbohydrazid
pyrazol
display
signific
activ
taken
togeth
studi
suggest
optim
substitut
isoxazolyl
moieti
phenyl
scaffold
keep
nh
group
linker
may
provid
opportun
improv
bind
affin
specif
substitut
cyanid
analogu
toward
epac
protein
summari
seri
substitut
cyanid
deriv
design
synthes
biolog
evalu
respect
inhibitori
capabl
toward
epac
protein
sar
result
base
activ
consist
dock
studi
indic
modif
phenyl
scaffold
isoxazol
moieti
may
allow
us
tune
origin
hit
achiev
potent
epac
antagonist
interestingli
variou
linker
explor
led
signific
loss
activ
indic
linker
parent
compound
play
critic
role
bind
activ
toward
epac
furthermor
sever
new
molecul
compound
identifi
potent
inhibitor
ic
valu
low
micromolar
submicromolar
rang
compound
may
hold
promis
potenti
drug
candid
preclin
develop
inden
studi
toward
novel
therapeut
human
diseas
addit
smallmolecul
inhibitor
may
serv
valuabl
pharmacolog
probe
facilit
effort
elucid
physiolog
function
epac
diseas
associ
signal
pathway
studi
select
compound
variou
human
diseas
model
systemat
optim
base
upon
identifi
advanc
chemic
lead
toward
epac
subtyp
select
way
report
due
cours
commerci
avail
start
materi
solvent
reagent
grade
use
without
purif
reaction
perform
nitrogen
atmospher
dri
glasswar
magnet
stir
prepar
column
chromatographi
perform
use
silica
gel
particl
size
mm
mesh
flash
analyt
tlc
carri
employ
silica
gel
f
plate
merck
darmstadt
visual
develop
chromatogram
perform
uv
detect
nm
nmr
spectra
record
h
mhz
c
mhz
spectromet
h
c
nmr
spectra
record
tm
intern
refer
chemic
shift
express
ppm
j
valu
given
hz
highresolut
mass
spectra
hrm
obtain
thermo
fisher
ltq
orbitrap
elit
mass
spectromet
paramet
includ
follow
nano
esi
spray
voltag
kv
capillari
temperatur
resolut
ioniz
achiev
posit
mode
melt
point
measur
thermo
scientif
electrotherm
digit
melt
point
apparatu
uncorrect
puriti
final
compound
establish
analyt
hplc
carri
shimadzu
hplc
system
model
uvvi
hplc
analysi
condit
follow
water
mm
flow
rate
mlmin
uv
detect
nm
linear
gradient
acetonitril
water
acetonitril
water
min
follow
min
lastnam
solvent
tfa
ad
acetonitril
water
biolog
evalu
compound
pure
solut
pinacolon
mg
mmol
thf
ml
ad
nah
mg
mmol
reaction
mixtur
stir
rt
min
diethyl
oxal
mg
mmol
ad
mixtur
stir
rt
overnight
result
solut
ad
hydroxylamin
hydrochlorid
mg
mmol
ethanol
ml
dropwis
mixtur
heat
reflux
h
time
sodium
chlorid
remov
filtrat
filtrat
concentr
reduc
pressur
residu
purifi
short
column
chromatographi
silica
gel
elut
hexaneethyl
acet
provid
colorless
oil
mg
h
nmr
mhz
cdcl
q
j
hz
j
hz
compound
prepar
yield
two
step
aceton
procedur
similar
use
prepar
compound
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
compound
prepar
yield
two
step
acetophenon
procedur
similar
use
prepar
compound
solut
ch
cn
mg
mmol
anhydr
thf
ml
ad
methyl
lithium
diethyl
ether
ml
mmol
nitrogen
mixtur
stir
h
g
mmol
thf
ml
ad
dropwis
solut
stir
h
quench
acet
acid
ml
mmol
mixtur
warm
pour
onto
icewat
ml
extract
ethyl
acet
ml
organ
lay
dri
na
filter
concentr
reduc
pressur
crude
residu
mg
obtain
yellow
oil
directli
use
next
step
without
purif
solut
anilin
mg
mmol
h
ml
cool
ad
ml
n
hcl
aq
result
acid
anilin
solut
ad
ml
solut
sodium
nitrit
mg
mmol
h
dropwis
gener
aryldiazonium
salt
solut
aryldiazonium
salt
solut
ad
sodium
acet
mg
mmol
follow
ml
solut
crude
mg
mmol
ethanol
reaction
mixtur
stir
min
pour
onto
h
ml
extract
ethyl
acet
ml
organ
layer
dri
na
filter
concentr
reduc
pressur
residu
purifi
short
column
chromatographi
silica
gel
elut
hexaneethyl
acet
provid
desir
product
mg
two
step
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
h
nmr
mhz
dmsod
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
solut
mg
mmol
cyanoacet
acid
mg
mmol
ml
dcm
ad
dipea
mg
mmol
edci
mg
mmol
ad
result
mixtur
stir
rt
h
solut
dilut
dcm
ml
wash
n
hcl
aq
ml
brine
ml
organ
layer
dri
anhydr
na
concentr
reduc
pressur
residu
purifi
silica
gel
column
chromatographi
hexan
etoac
give
desir
product
white
solid
mg
solut
mg
mmol
h
ml
cool
ad
ml
n
hcl
aq
result
acid
anilin
solut
ad
ml
solut
sodium
nitrit
mg
mmol
h
dropwis
gener
aryldiazonium
salt
solut
aryldiazonium
salt
solut
ad
sodium
acet
mg
mmol
follow
ml
solut
mg
mmol
ethanol
reaction
mixtur
stir
min
pour
onto
h
ml
extract
ethyl
acet
ml
organ
layer
dri
na
filter
concentr
reduc
pressur
residu
purifi
short
column
chromatographi
silica
gel
elut
hexaneethyl
acet
provid
desir
product
compound
prepar
yield
two
step
procedur
similar
use
prepar
compound
titl
compound
obtain
yellow
solid
mp
hplc
puriti
r
min
solut
acid
mg
mmol
ml
dcm
ad
cocl
mmol
mixtur
allow
stir
rt
h
solut
concentr
dissolv
ml
dcm
tertbutyl
mg
mmol
et
n
mg
mmol
ad
mixtur
stir
rt
overnight
solut
dilut
dcm
wash
n
nahso
satur
nahco
brine
ml
organ
layer
concentr
purifi
ptlc
obtain
mg
white
solid
mp
hplc
puriti
r
min
mixtur
tertbutyl
mg
mmol
mg
mmol
ml
dcm
stir
rt
overnight
mixtur
concentr
vacuum
residu
purifi
silica
gel
column
hexaneetoac
obtain
mg
mmol
lioh
mg
mmol
dissolv
ml
meoh
ml
h
respect
solut
stir
rt
h
icecool
bath
n
na
ml
ad
mixtur
extract
ethyl
acet
ml
organ
layer
separ
wash
brine
ml
dri
anhydr
na
solut
concentr
give
acid
light
yellow
oil
mg
ethyl
tertbutyl
mg
mmol
nh
nh
mg
mmol
dissolv
ml
etoh
reflux
h
ad
solut
allow
stir
rt
overnight
solut
concentr
extract
dcm
ml
dri
anhydr
na
solut
concentr
purifi
silica
gel
column
hexaneetoac
obtain
mg
two
step
white
solid
mp
hplc
puriti
r
min
solut
mg
mmol
etoh
ml
ad
hydrazin
hydrat
mmol
reaction
mixtur
reflux
h
solvent
evapor
crude
product
crystal
dichloromethan
yield
yellow
solid
mp
yield
mg
hplc
puriti
r
min
h
nmr
mhz
dmsod
j
hz
j
hz
substitut
cyanid
analogu
dock
use
xray
structur
pdb
code
autodock
water
molecul
ligand
spcamp
within
crystal
structur
remov
polar
hydrogen
ad
use
autodocktool
structur
analogu
bond
treat
rotat
except
aromat
amid
cyano
doubl
bond
wherea
protein
treat
rigid
dock
run
carri
use
standard
paramet
program
interact
grow
subsequ
score
except
paramet
set
grid
box
dimens
center
dock
studi
grid
box
size
center
coordin
x
z
pdb
structur
use
bind
affin
output
structur
rang
kcalmol
solubl
water
ethanol
determin
hplc
analysi
accord
previous
publish
protocol
first
mg
weigh
ad
ml
water
mg
weigh
ad
ml
ethanol
suspens
shaken
h
centrifug
supernat
filter
aliquot
supernat
inject
hplc
system
equip
reversephas
column
condit
describ
experiment
section
gener
chemistri
inform
onepoint
calibr
recombin
fulllength
human
mous
ctermin
truncat
purifi
previous
describ
competit
assay
perform
micropl
corn
costar
cambridg
usa
previous
describ
reaction
mix
contain
nm
nm
mm
trishcl
ph
buffer
mm
nacl
mm
edta
mm
ddt
dispens
plate
test
compound
ad
reaction
mix
differ
dose
fluoresc
intens
signal
probe
addit
test
compound
measur
use
micropl
reader
molecular
devic
silicon
valley
ca
usa
excitationemiss
wavelength
set
nm
lastli
fluoresc
intens
monitor
addit
camp
satur
final
concentr
data
present
normal
observ
fluoresc
intens
f
initi
floresc
signal
f
addit
compound
final
floresc
signal
camp
addit
f
camp
use
follow
equat
rel
fluoresc
f
f
camp
f
f
camp
vitro
gef
activ
acquir
previous
describ
briefli
assay
perform
use
nm
nm
buffer
contain
mm
trishcl
ph
mm
nacl
mm
mgcl
mm
dtt
mm
gdp
indic
concentr
test
compound
room
temperatur
use
half
area
plate
corn
costar
exchang
reaction
monitor
use
spectramax
plate
reader
molecular
devic
excitationemiss
wavelength
set
nm
reaction
rate
constant
k
ob
determin
global
fit
experiment
data
singleexponenti
equat
quantif
process
normal
observ
k
ob
presenc
inhibitor
rate
constant
presenc
camp
inhibitor
k
camp
rate
constant
without
camp
inhibitor
k
use
follow
equat
rel
gef
activ
k
ob
k
k
camp
k
refer
web
version
pubm
central
supplementari
materi
c
ne
effect
indic
specif
ic
calcul
data
point
collect
